A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

NCT03100825 | Completed Phase 3 Results

• 1 other identifier: CQVM149B1304
• Study Type: interventional
• Target: 96
• Locations: 1 country
• Sites: 25

Brief Summary

The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.

Conditions

Asthma

Keywords

QVM149; Asthma; Japanese; Allergic asthma; Allergy triggered asthma; Reactive asthma; Asthma attack; Difficulty breathing

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)

  An adverse event (AE) was any untoward medical occurrence (example; any unfavorable and unintended sign including abnormal laboratory findings, symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study until the end of study visit. TEAEs were defined as adverse events started on or after the time of the first inhalation of study drug but no later than 7 days after the last administration (30 days in the case of SAEs). SAE was defined as any adverse event (appearance of \[or worsening of any pre-existing\]) undesirable sign, symptom or medical conditions which is fatal or life-threatening or results in persistent or significant disability/incapacity or constitutes a congenital anomaly/birth defect or requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.

  Up to 52 Weeks

Secondary Outcomes (6)

• Change From Baseline (Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 26 and 52

  Baseline (Pre-dose), Week 26, Week 52

• Change From Baseline (Pre-dose) Forced Vital Capacity (FVC) at Week 26 and 52

  Baseline (Pre-dose), Week 26, Week 52

• Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) Over 52 Weeks

  Baseline up to week 52

• Change From Baseline in Asthma Control Questionnaire-7 (ACQ-7) Total Score at Week 26 and 52

  Baseline, Week 26, Week 52

• Proportion of Participants Who Achieved Clinically Meaningful Improvement Threshold in ACQ-7 Score (Decrease of Greater Than or Equal to 0.5 Units in ACQ-7) at Week 26 and 52

  Week 26, Week 52

Study Arms (1)

QVM149

EXPERIMENTAL

All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.

Drug: QVM149

Interventions

QVM149 DRUG

QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)

Also known as: QVM149 150/50/160 μg once daily, delivered as powder in hard capsules via Concept1 inhaler

QVM149

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent must be obtained before any assessment is performed.
• Male and female adult patient ≥ 18 years old.
• Patients with a diagnosis of persistent asthma (GINA 2016) for a period of at least 1 year prior to Visit 1.
• Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3 months and at stable dose and regimen for at least 4 weeks prior to Visit 1.
• An ACQ-7 score ≥ 1.5 at Visits 2.
• Pre-bronchodilator FEV1 of ≥ 40% and ≤ 85% of the predicted normal value for the patient after withholding bronchodilators at Visit 2.
• o Repeating is allowed once only. Repeating of percentage predicted FEV1 should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before Visit 99.
• Patients must demonstrate reversibility defined as an increase in FEV1 of ≥ 12% and 200 mL within 15 to 30 minutes after administration of 400 µg of salbutamol at Visit 2. Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing.
• If reversibility is not proven at Visit 2, patients may be permitted to enter the study with historical evidence of reversibility that was performed within 5 years prior to Visit 1.
• Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test (defined as a provoked fall in FEV1 of 20% by bronchoconstriction agent e.g., methacholine, histamine) or equivalent test (e.g., astography) that was performed within 5 years prior to Visit 1.
• If reversibility is not proven at Visit 2 and historical data is not available, reversibility should be repeated once in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day).

You may not qualify if:

• Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6-weeks of Visit 1.
• Patients who have ever required intubation for a severe asthma attack/exacerbation.
• Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.
• Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered.
• Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 99. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.
• Patients with a history of chronic lung diseases other than asthma, including (but not limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
• Patients with severe narcolepsy and/or insomnia
• Pregnant or nursing (lactating) women
• Women of child-bearing potential unless they are using highly effective methods of contraception during dosing and for 30 days after stopping of investigational medication

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (25)

Novartis Investigative Site

Koga, Fukuoka, 811 3195, Japan

Location

Novartis Investigative Site

Yanagawa, Fukuoka, 832-0059, Japan

Location

Novartis Investigative Site

Maebashi, Gunma, 371-0054, Japan

Location

Novartis Investigative Site

Hiroshima, Hiroshima, 732-0052, Japan

Location

Novartis Investigative Site

Sapporo, Hokkaido, 001-0901, Japan

Location

Novartis Investigative Site

Tomakomai, Hokkaido, 053-8506, Japan

Location

Novartis Investigative Site

Takamatsu, Kagawa-ken, 761-8073, Japan

Location

Novartis Investigative Site

Fujisawa, Kanagawa, 251-0041, Japan

Location

Novartis Investigative Site

Sagamihara, Kanagawa, 228-8522, Japan

Location

Novartis Investigative Site

Sagamihara, Kanagawa, 229-1103, Japan

Location

Novartis Investigative Site

Yokohama, Kanagawa, 236 0051, Japan

Location

Novartis Investigative Site

Yokkaichi, Mie-ken, 510-8561, Japan

Location

Novartis Investigative Site

Nagaoka, Niigata, 940-2085, Japan

Location

Novartis Investigative Site

Osaka, Osaka, 530 0001, Japan

Location

Novartis Investigative Site

Sakai, Osaka, 591 8037, Japan

Location

Novartis Investigative Site

Ageo, Saitama, 362-8588, Japan

Location

Novartis Investigative Site

Chuo Ku, Tokyo, 104-0031, Japan

Location

Novartis Investigative Site

Chuo-ku, Tokyo, 103-0003, Japan

Location

Novartis Investigative Site

Chuo-ku, Tokyo, 103-0027, Japan

Location

Novartis Investigative Site

Chuo-ku, Tokyo, 103-0028, Japan

Location

Novartis Investigative Site

Ōta-ku, Tokyo, 145 0063, Japan

Location

Novartis Investigative Site

Setagaya-ku, Tokyo, 158-0097, Japan

Location

Novartis Investigative Site

Setagaya-ku, Tokyo, 158-8531, Japan

Location

Novartis Investigative Site

Shinagawa-ku, Tokyo, 142-8666, Japan

Location

Novartis Investigative Site

Toshima Ku, Tokyo, 170 0003, Japan

Location

MeSH Terms

Conditions

Asthma; Dyspnea

Interventions

Parturition; Powders; Hardness

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pregnancy; Reproduction; Reproductive Physiological Phenomena; Reproductive and Urinary Physiological Phenomena; Dosage Forms; Pharmaceutical Preparations; Mechanical Phenomena; Physical Phenomena

Results Point of Contact

• Title: Study Director
• Organization: Novartis Pharmaceuticals

novartis.email@novartis.com

862-778-8300

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 29, 2017
• First Posted: April 4, 2017
• Study Start: April 28, 2017
• Primary Completion: September 18, 2018
• Study Completion: April 8, 2019
• Last Updated: April 7, 2020
• Results First Posted: April 7, 2020

Record last verified: 2020-03

Locations

JP (25)